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The antineoplastic potential of a stable monomeric Au(II) complex with hematoporphyrin IX (Hp), namely [Au(II)Hp-2H.
(H2O)2], was investigated in a panel of tumor cell lines. The complex exhibits strong cytotoxicity, whereby the leukaemia- and
lymphoma-derived cell lines are more sensitive, with IC50 values comparable to those of the reference anticancer drug cisplatin.
In contrast, the solid tumor models are more sensitive to the platinum drug. A comparative assessment of both agents against the
human kidney cell line 293T has shown that [Au(II)Hp-2H.(H2O)2] is less cytotoxic. The gold complex induces oligonucleosomal
DNA fragmentation in tumour cells following 24-hour treatment and hence its cytotoxic eﬀect is at least partly mediated by
induction of apoptotic cell death. A prominent intracellular gold accumulation was detected after treating tumor cells with
[Au(II)Hp-2H.(H2O)2] which shows that its putative pharmacological targets are readily accessible after a short incubation period.
Copyright © 2008 Georgi Momekov et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cisplatin and the structurally related platinum-based drugs
represent one of the most important classes of antineoplastic
agents, being especially valuable for the treatment of germ
cell cancer and a variety of other solid malignancies [1–3].
Despite their important clinical role, however, the platinum-
based chemotherapeutics possess relatively low selectivity to
malignant cells and hence their application is associated with
signiﬁcant dose-limiting organ toxicities [1]. Beside their
unfavorable safety proﬁle, the major limitation in the clinical
application of the currently marketed platinum agents is the
development of acquired resistance by the tumor cells [2].
Consequently, a signiﬁcant interest is manifested towards the
design and synthesis of cisplatin-dissimilar analogues with
modiﬁed pharmacological properties capable of bypassing
the cellular resistance mechanisms [4–6].
Considering the fact that the thermodynamic stability
and kinetic behavior of the metal complexes in biological
milieu and hence their biochemical and pharmacological
properties depend greatly on the nature of the adduct-
forming metal centers, it is well appreciated that a change
of the metal ion could alter the antineoplastic activity [6].
Among the nonplatinum metal-based chemotherapeutics
much attention has been paid to gold complexes [7]. Well
known for their clinical antiarthritic application [8], the
gold-based drugs have also attracted interest as potential
antineoplastic agents with gold(I)-phosphine derivatives2 Bioinorganic Chemistry and Applications
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Figure 1: Chemical structure of the tested gold complex [Au-
(II)Hp-2H.(H2O)2].
being among the most active in vivo against murine
tumor models [9]. Currently, the greatest interest towards
development of gold-based chemotherapeutics is focused
on the Au(III) compounds which being isoelectronic with
platinum(II) share the propensity of forming square planar
complexes, analogous to cisplatin [7, 10]. It could be
anticipated that similar to Pt(II) compounds, the gold(III)
species are capable of binding on DNA and this is the
reason for their cytotoxicity. Unlike platinum(II), however,
the gold(III) complexes are extremely unstable under phys-
iological conditions which practically preclude the interest
towards this class of metal-based drugs. In addition, the
gold(III)complexesarehighlyreactiveandareabletooxidize
a series of biomolecules such as methionine, glycine, and
albumin leading to a quick reduction to gold(I) or even to
elemental gold [10–12]. It has been proven that the stability
of Au(III) compounds can be augmented by bonding with
nitrogen donor-containing bi- and multidentate chelating
ligands such as ethylendiamine, cyclam, bipyridine, and
so forth, that lower the redox potential of the metal
center [10, 13, 14]. Recently, a large number of reports on
the preparation, structural characterization, and cytotoxic
studies of stable gold(III) complexes and organometallic
compounds appeared in the scientiﬁc literature [10].
With regard to redox stability and kinetic behavior,
the search for proper cytotoxic gold(II) complexes is an
intriguingandpreviouslyunexploredareaofanticancerdrug
design. Nowadays, the Au(II) oxidation state can be consid-
ered as a common state in gold chemistry. Despite the large
number of stable diamagnetic dinuclear and polynuclear
gold(II) complexes, the examples of mononuclear ones are
scarce and most of them are with S-containing ligands [15–
17]. Recently, the synthesis and structural characterization
of a stable monomeric hematoporphyrin Au(II) complex
with general formula [Au(II)Hp-2H.(H2O)2]( Figure 1)a n d
distorted octahedral structure has been reported [18]. Au(II)
species are stabilized in the complex through coordination
via the four nitrogen atoms of the porphyrin macrocycle and
the two water molecules are in axial position.
The rationale design for synthesizing porphyrin-based
metal complexes as anticancer drugs is based on their
selective accumulation within malignant tissue together with
participation in augmentation of the cytotoxicity upon light
irradiation. Hence, such complexes are expected to behave
like hybrid drugs with combined cytotoxic/phototoxic prop-
erties [4]. Brunner and coworkers have described large series
of planar platinum(II)-porphyrin conjugates whereby the
metalcentersarecoordinatedwiththeporphyrinresiduesvia
the pendant functionalities [19–21]. Recently, we have syn-
thesized and characterized three stable octahedral platinum
hematoporphyrin complexes in the unusual oxidation state
of platinum 3+. In these complexes the hematoporphyrin
ligand is coordinated as follows: via four pyrrole N-atoms
forming metalloporphyrin type complex; or by asymmetric
coordination through two N-atoms from adjacent pyrrole
rings forming SAT-type complex; or by the side chains pro-
pionic COO−groups outside the porphyrin macrocycle. The
complexes displayed signiﬁcant cytotoxic and proapoptotic
activities against human tumor cell lines [22].
This study deals with the cytotoxic activity of the newly
synthesized stable gold(II) complex Au(II)Hp-2H.(H2O)2
againstaspectrumoftumorcelllines.Itseﬀectonthehuman
epidermal kidney cell line 293T has been studied as well in
order to estimate the selectivity of cytotoxicity.
2. MATERIALS AND METHODS
2.1. Chemicalsandreagents
RPMI-1640 and DMEM growth media, fetal calf serum,
and L-glutamine were purchased from 3. Sigma-Aldrich
Co, “St. Louis”, Missouri, USA. (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT)- Triton X-100,
gold standard, Tris HCl, DMSO, and EDTA were supplied
from Merck Co.
The gold(II) complex with hematoporphyrin—[Au(II)-
Hp-2H.(H2O)2] was synthesized as previously described [18].
The reference anticancer drug cisplatin was purchased from
Sigma. Stock solutions of both agents were freshly prepared
in DMSO and promptly diluted serially with RPMI-1640
medium to the desired extent. The DMSO concentration
never exceeded 1% in the ﬁnal dilutions obtained.
2.2. Celllinesandcultureconditions
T h eT - c e l ll e u k a e m i aS K W - 3( aK E - 3 7d e r i v a t i v e )( D S M Z
No.: ACC 53); the nonHodgkin lymphoma DOHH-2
(DSMZ No.: ACC 47); the chronic myeloid leukaemias K-
562 (DSMZ No. ACC 10), and LAMA-84 (DSMZ No. ACC
168) as well as the urinary bladder carcinoma-derived 5637
(DSMZ No.: ACC 35) were obtained from DSMZ GmbH
(Braunschweig , Germany). The human urinary bladder
carcinoma cell line MGH-U1 was supplied by American
Type Cell Culture (Rockville, MD, USA). The cells were
maintained as suspension type cultures (leukaemias) or
as adherent cultures (5637 and MGH-U1) in controlled
environment: RPMI-1640 medium, supplemented by 10%
heat-inactivated fetal calf serum and 2mM L-glutamine, atGeorgi Momekov et al. 3
37◦C in a “Heraeus” incubator with 5% CO2 humidiﬁed
atmosphere. In order to keep cells in log phase, the cultures
were refed with fresh RPMI-1640 medium two or three
times/week.
2.3. Cytotoxicityassay
Cell viability was assessed using the standard MTT-dye
reduction assay as previously described [23]with minor
modiﬁcations [24]. Exponentially growing cells were seeded
in 96-well ﬂat-bottomed microplates (100μL/well) at a
density of 1 × 105 cells per mL and after 24-hour incubation
at 37◦C; they were exposed to various concentrations of
the tested complexes for 72 hours. For each concentration
at least 8 wells were used. After the incubation with
the test compounds MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma) solution (10mg/mL
in PBS) was added (10μL/well). Microplates were further
incubated for 4 hours at 37◦C and the quantity of for-
mazan product obtained was determined spectrophotomet-
rically using a microprocessor-controlled multiplate reader
(Labexim LMR-1) at 580nm. The cell survival fractions were
calculated as percentage of the untreated control (untreated
control =100%).Theexperimentaldataweretransformedto
sigmoidal dose-response curves using nonlinear regression
analysis (GraphPad Prizm), which enabled the calculation of
the corresponding IC50 values.
2.4. DNAfragmentationanalysis
The characteristic for apoptosis mono- and oligonucleo-
somal fragmentation of genomic DNA was detected using
“Cell Death Detection” ELISA kit (Roche Diagnostics, Ger-
many). The exponentially growing MGH-U1, K-562, HD-
MY-Z, and SKW-3 cells were plated in sterile petry dishes
and exposed to equipotent concentrations for 24 hours.
Cytosolic fractions of 1 × 104 cells per group (treated or
untreated) served as antigen source in a sandwich ELISA
utilizing primary antihistone antibody-coated microplate
and a secondary peroxidase-conjugated anti-DNA antibody.
The photometric immunoassay for histone-associated DNA
fragments was executed in accordance with the manufac-
turer’s instructions at 405nm using ELISA reader (Labexim
LMR-1). The results were expressed as the oligonucleosome
enrichmentfactorrepresentingtheratiobetweentheabsorp-
tion in the treated versus the untreated control samples.
2.5. Cellularaccumulationkinetics
Aliquots of 2 × 107 K-562 cells and HD-MY-Z cells (in
2mL RPMI 1640) were placed in sterile petry dishes and
exposed to diﬀerent concentrations of the gold complex:
(12.5, 25, 50, and 100μM) for 30 or 60 minutes. After
the exposure period, the cells were spun at 2000rpm for
5 minutes and the drug-containing medium was discarded.
The cells were then washed thrice with phosphate buﬀered
saline and aliquots were taken for counting and cell viability
determination (trypan blue dye exclusion assay). Thereafter,
the cells were digested in 50μL 10% Triton X100 (EDTA) for
5 minutes, and 950μL mixture of concentrated hydrochloric
acid and concentrated nitric acid (3 : 1) was added in
order to allow complete decomposition of the cells, and
dissolution of the accumulated gold complex for 1 hour.
Following the complete decomposition of the cells, the
volume of the samples was adjusted to 1mL and the gold
concentration was determined. The gold concentrations in
the sample solutions higher than 0.5μg/mL were determined
using ﬂame atomic absorption spectrometry (FAAS) with
an air-acetylene ﬂame (PYE UNICAM SP 1950). Lower
gold concentrations were determined by electrothermal AAS
using a Perkin-Elmer Zeeman 3030 spectrometer with an
HGA-600 graphite furnace. The light source was a hollow
cathode lamp for Au. The spectral bandpass was 0.7nm.
S t a n d a r du n c o a t e dg r a p h i t et u b e sw e r eu s e da sa t o m i z e r .
Only peak areas were used for quantiﬁcation. The results
were expressed as nmol gold/106 cells.
2.6. Dataprocessingandstatistics
The cytotoxicity assays were carried out in eight separate
experiments,whereastheapoptosisinductionevaluationwas
conducted in quadruplicate. The data processing exploited
MS Excel and GraphPad Prizm software for PC. Student’s t-
test was performed with P ≤ .05 taken as signiﬁcance level.
3. RESULTS
3.1. Cytotoxicityagainsttumorcelllines
The cytotoxic potential of the novel Au(II) complex was
studied in a panel of malignant cell lines, originating
from leukaemias, lymphomas, and solid tumors. The results
of the chemosensitivity screening program, following 72-
hour treatment, are summarized in Table 1. Throughout
the screening investigation cisplatin was used as a positive
control.
The cytotoxic eﬀects of the Au(II) complex were eval-
uated using the concentration-response curves presented
in Figure 2. The cellular viability was reduced signiﬁcantly
causing 50% inhibition at micromolar concentrations in the
majority of the cell lines tested.
Generally, the leukaemia and lymphoma-derived cell
lines were more sensitive to the Au(II) complex and the
IC50 values obtained were comparable to those of the
referent anticancer drug cisplatin. Among them the most
responsive tumor model was the T-cell leukaemia SKW-
3 (KE-37 derivative) (Table 1, Figure 2). Against this cell
line the relative potency of [Au(II)Hp-2H.(H2O)2]e v e n
surpassed that of cisplatin. In contrast, the solid-tumor-
derived cell lines showed far more pronounced sensitivity
to cisplatin as compared to the novel gold(II) complex. The
murine neuroblastoma Neuro2A was resistant to both metal
complexes.4 Bioinorganic Chemistry and Applications
Table 1: IC50 values of Au(II)Hp-2H.(H2O)2 and cisplatin against a panel of tumor cell lines assessed after 72-hour exposure (MTT-dye
reduction assay).
Cell line Origin/Cell type IC50(μM)
Au(II)Hp-2H.(H2O)2 cisplatin
LAMA-84 chronic myeloid leukaemia 65.1 20.3
K-562 chronic myeloid leukaemia 161.2 32.0
SKW-3(a) T-cell leukaemia 7.6 11.7
DOHH-2 nonHodgkin lymphoma 50.1 35.0
HD-MY-Z Hodgkin’s lymphoma 43.1 12.2
MGH-U1(b) urinary bladder cancer 56.4 5.9
MCF-7 breast cancer 166.8 33.4
SAOS-2 osteogenic sarcoma >200 15.2
Neuro-2a murine neuroblastoma >200 >200
(a)KE-37 derivative;
(b) Formerly designated as EJ.
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Figure 2: Concentration-response curves of [Au(II)Hp-2H.(H2O)2]( )a n dc i s p l a t i n( ) against a panel of tumor cell lines as assessed by
the MTT-dye reduction assay after 72-hour exposure. Each data point represents the arithmetic mean ±sd of eight separate experiments.Georgi Momekov et al. 5
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Figure 3: Cytotoxic eﬀects of [Au(II)Hp-2H.(H2O)2]( )a n d
cisplatin () against the human embryonic kidney cell line 293T as
assessed by the MTT-dye reduction assay after 72 hours exposure.
Each data point represents the arithmetic mean ±sd of eight
separate experiments.
3.2. Invitrocytotoxicitystudyof[Au(II)Hp-2H.(H2O)2]
onhumankidneycellsincomparisontocisplatin
The nephrotoxicity of the novel compound in an in
vitro test system versus the established nephrotoxic drug
cisplatin was estimated. The human embryonic kidney
293T cells were exposed for 72 hours to either cisplatin
or [Au(II)Hp-2H.(H2O)2] and thereafter, their viability was
detectedwithMTT-dyereductionassay(Figure 3).Through-
out the tested range of concentrations the gold(II) complex
proved to be only marginally cytotoxic and failed to cause
50% reduction of cell viability. In contrast, the referent
drug cisplatin exhibited more pronounced cytotoxicity upon
kidney cells with an IC50 value of 3.87μM.
3.3. Inductionofapoptosisfollowing
[Au(II)Hp-2H.(H2O)2]treatment
Despite their principle modes of action, the majority of anti-
cancerdrugssharethedistinctionofbeingcapableofrecruit-
ing the apoptotic cell death signaling pathways in malignant
cells.Therefore,theabilityof[Au(II)Hp-2H.(H2O)2]toev ok e
genomic DNA-fragmentation which is a key hallmark of
programmed cell death was investigated. For this purpose,
the exponentially growing SKW-3, K-562, HD-MY-Z, and
MGH-U1 cells were exposed to equieﬀective concentrations
of the gold(II) complex or cisplatin for 24 hours and there-
after, the levels of oligonucleosomal DNA fragmentation
were assessed using a commercially available ELISA kit
(Figure 4).
The results obtained indicate that [Au(II)Hp-2H.(H2O)2]
is a potent apoptosis inductor causing similar level of DNA
fragmentation as the referent drug cisplatin if applied at
equipotent concentrations. The eﬀect of the gold complex
in MGH-U1 and HD-MY-Z was characterized by a straight-
forward concentration dependence, whereby the proportion
of apoptotic cells arise increasing the concentration. In a
contrast, the level of oligonucleosomal DNA-fragmentation
was found to decrease at the highest concentration as
compared to the lower ones in SKW-3. This result could be
ascribed to the relative increase of the proportion of necrotic
cells undetectable in our experimental setting. The gold
complex failed to induce prominent DNA-fragmentation in
K-562 cells throughout the concentration range used. The
level of apoptosis was signiﬁcantly higher than the control
only after exposure of cells to the highest concentration
(twice the IC50 value).
3.4. Intracellularaccumulationof[Au(II)Hp-2H.(H2O)2]
The determination of the intracellular levels of gold attained
after 30 minutes or 60 minutes of treatment of either
K-562 cells or HD-MY-Z with the Au(II) complex is
depicted on Figure 5. A prominent time- and concentration-
dependent pattern of gold accumulation is evident, whereby
the intracellular levels in the K-562 cells are substantially
higher as compared to those in HD-MY-Z cells. These data
indicate that putative pharmacological targets of the tested
compounds are readily accessible after a short incubation
period.
4. DISCUSSION
To our best knowledge, the present study is the ﬁrst one
addressing the cytotoxic potential of stable monomeric
octahedral Au(II) complexes. The antiproliferative activity
of the novel compound was evaluated in a wide spectrum
of cell lines, representative for some important types of
human cancer. The results of the MTT-dye reduction assay
unambiguously indicate that [Au(II)Hp-2H.(H2O)2]e x e r t s
potent cytotoxic/antiproliferative eﬀect which in some cases
is comparable to that of the referent cytotoxic drug cisplatin.
Among the cell lines under evaluation the human T-cell
leukaemia SKW-3 proved to be the most sensitive to Au(II)-
complex treatment, actually the IC50 value in these cells
was lower than cisplatin. In the other leukaemia models,
the relative potency of [Au(II)Hp-2H.(H2O)2] was somewhat
lower but more or less comparable to that of cisplatin. Our
experimental data indicated that cisplatin was prominently
superior against the solid tumor-derived cell lines.
The clinically used platinum drugs as well as the
gold antirheumatic agents are characterized by signiﬁcant
nephrotoxicity which is recognized as major dose-limiting
factor. Hence, we sought to determine the nephrotoxic
potential of [Au(II)Hp-2H.(H2O)2] versus the established
nephrotoxin cisplatin. The transformed cell lines appear to
be an attractive model among the in vitro test systems used
for assessment of nephrotoxicity. They are more versatile
than the primary cells on the one hand and retain most
of the biochemical features of the normal kidney tissue on
the other hand [25]. In the present study, 293T cells were
used which have been recently characterized as a suitable
model for in vitro assessment of nephrotoxicity [26–28]. The
newly synthesized complex [Au(II)Hp-2H.(H2O)2]p r o v e st o
be far less cytotoxic against kidney cells and in contrast to
cisplatin, it fails toinduce 50% inhibition of cellularviability.
In contrast cisplatin was found to exert prominent cytotoxic6 Bioinorganic Chemistry and Applications
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Figure 4: Internucleosomal DNA fragmentation in SKW-3, K-562, HD-MY-Z, and MGH-U1 cells after 24-hour exposure to equipotent
concentrations of [Au(II)Hp-2H.(H2O)2] (white columns) or cisplatin (gray columns). The level of DNA fragmentation expressed as the
corresponding enrichment factor (ef = 1 in untreated control) was determined using “Cell Death Detection” ELISA (Roche Diagnostics).
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Figure 5: Intracellular accumulation of gold following [Au(II)Hp-2H.(H2O)2] treatment of HD-MY-Z or K-562 cells for 30 minutes (white
columns) or 60 minutes (gray columns), means of 4 independent experiments.
eﬀects with the IC50 value similar to those obtained in the
cancer cell lines.
Another important objective of the present investigation
was to determine the intracellular penetration of the gold
complex. Although the speciﬁc mechanisms of the cytotoxi-
city of gold species are not fully elucidated, there is a general
consensus that they interact with intracellular targets, a
featurewhichiscommonformostoftheanticancerdrugs[7,
10].Thus,thecellularaccumulationofthedrugappearstobe
acrucialprerequisiteforoptimalcytotoxicactivity.ThenovelGeorgi Momekov et al. 7
gold(II)complexischaracterisedbyasigniﬁcantintracellular
accumulation which is more pronounced in the leukemic
model K-562 than in HD-MY-Z Hodgkin’s lymphoma. A
possible explanation is the discrepancy between the cultures
typeinthesecelllines.WhiletheK-562cellsaresuspendedin
themedium,theHD-MY-Zcellstendtoattachtothebottom
of the cultivation vessel forming monolayers. Conversely, the
exposure area in K-562 cells is greater in comparison to that
of the semiadherent HD-MY-Z.
In order to elucidate the mechanisms underlying the
observed cytotoxicity of [Au(II)Hp-2H.(H2O)2], the level of
DNA-fragmentation has been quantiﬁed. The induction of
programmed cell death appears to be a common feature
mediating the cytotoxic eﬀects of anticancer agents and in
particular of metal-based drugs [1, 4]. The results reported
here conﬁrm the general character of this phenomenon:
[Au(II)Hp-2H.(H2O)2] was found to induce apoptotic cell
death in SKW-3, MGH-U1, K-562, and HD-MY-Z cells after
24-hour exposure. The low responsiveness of K-562 cells to
theproapoptotic eﬀectsof[Au(II)Hp-2H.(H2O)2]isthemost
probable explanation for the discrepancy between its low
sensitivity to the gold agent and its excellent intracellular
accumulation patterns.
The present data for the Au(II) metalloporphyrin com-
plex are in accordance with the eﬀects established with
structurally similar, octahedral Pt(III) complexes which are
characterized by a signiﬁcant cytotoxicity too [22]. The
complex [Au(II)Hp-2H.(H2O)2] has an analogous structure
with one of these Pt(III) complexes, both having octahedral
structure with the metal center being coordinated in the por-
phyrinringviathefourpyrrolicnitrogens.Thejuxtaposition
of their cytotoxicity shows that while the platinum complex
is far more active against the chronic myeloid leukaemia
LAMA-84 [18], the Au(II) complex studied exerts superior
activity against the T-cell leukaemia SKW3 (KE-37). These
data correlate well with the estimated speciﬁc inhibiting
eﬀect of gold species upon immune cells and T-cells in
particular [7].
The selective uptake of porphyrins in malignant tis-
sues/cells is due to complex mechanisms, among them the
most important being the LDL-receptor mediated endocyto-
sis of porphyrin/lipoprotein complexes formed in the circu-
lation. Hence, porphyrins are employed as targeting moieties
to ensure selective accumulation of cytotoxic agents into the
solid tumor microenvironment [19–21]. The novel complex
used in the present study demonstrated signiﬁcant intra-
cellular accumulation presumably mediated by formation
of FCS-lipoprotein complexes and subsequent endocytosis.
Due to the phototoxic properties of the ligand, a light-borne
augmentation of the cytotoxicity of [Au(II)Hp-2H.(H2O)2]
could not be ruled out and would be addressed in a further,
more detailed evaluation of this compound.
All experimental data presented in this study indicate
that[Au(II)Hp-2H.(H2O)2]isabiologicallyactivecompound
with well-pronounced cytotoxic and proapoptotic properties
against malignant cells. As compared to cisplatin, it is less
cytotoxic for human kidney cells and this feature may prove
to be advantageous.
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